dallas semaglutide gastric stasis attorney vomiting law office lawyer firm dallas semaglutide Mohammad Y. Said-bsmoothhr dallas semaglutide nausea law – semaglutide law office – semaglutide intestinal paralysis attorney in

Major phase 2 publications describe gastrointestinal adverse events as commonly observed, consistent with the broader incretin class research landscape

Therefore, from a clinical perspective, primary treatment goals should focus on achieving metabolic health rather than weight loss alone

In February 2026, the FDA released a report alerting patients and providers about the risks of compounded GLP-1 medications

Stahl's prediction: MDD is five different illnesses [36:11] 2030 projection: over 50% of adults with obesity [37:27] Starting with clinicians practicing what they preach [38:44] Wild 5 Wellness program [40:34] Force multipliers: treating populations, not just individuals [43:06] Equipping other clinicians rather than scaling [43:48] Private practice summit planned for Vegas 2026 Thank you for reading/listening